SEC Tracker
Get the app

Exelixis EXEL

Michael Morrissey (EXEL) Chief Financial Officer Jane Doe reported selling 50,000 shares worth $1.2 million. This insider selling activity signals potential bearish sentiment from company leadership regarding the stock's near-term prospects.

Michael Morrissey, insider filing for EXEL

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Exelixis files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
  2. BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
  3. Roivant Sciences ROIV public float $9.8B, Sep 30, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.